Kisspeptin-10
Also known as: Kisspeptina-10
Molecular Identifiers
Molecular Formula
C63H83N17O14
CAS Number
374675-21-5
PubChem CID
25240297Molecular Weight
1302.4 Da
Overview
Upstream regulator of GnRH. Research in reproductive endocrinology. Highly variable dosage per study protocol.
The main clinical interest around Kisspeptin-10 is its role as an upstream regulator of GnRH: it acts on the GPR54 receptor in hypothalamic neurons and induces physiological release of GnRH, and consequently of LH and FSH. This allows assessment and modulation of the hypothalamic-pituitary-gonadal axis in central hypogonadism, delayed puberty, and infertility workup.
Kisspeptin-10 currently has no regulatory approval from any agency (FDA, EMA, ANVISA), and its use remains restricted to the clinical research context, mainly in reproductive endocrinology centers. Doses described in studies are highly variable depending on experimental design — from a diagnostic bolus to continuous infusions to induce puberty or ovulation. There is no established prescription in routine outpatient medicine.
Within the HPG axis, kisspeptin-10 is the only ligand acting upstream of GnRH, on the hypothalamic neurons themselves via GPR54 — different from gonadorelin (endogenous GnRH), triptorelin (agonist), and cetrorelix (antagonist), which act on the pituitary GnRH receptor, and from hCG, which acts directly on the gonad as an LH mimic. This upstream positioning makes it a unique research tool to assess the physiological integrity of the axis, but also limits established clinical use.
YNWNSFGLRF Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe Half-life
~4-5 minutes
Administration Route
Subcutaneous or intravenous
Category
Hormonal Regulation
Mechanism of Action
- Stimulation of GnRH release via GPR54 receptor
- Upstream regulation of the reproductive axis
- Modulation of pulsatile LH secretion
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-10 mcg per injection |
| Frequency | Per research protocol |
| Timing | Per study design |
| Duration | Per study |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Facial flushing
- Headache
- Nausea
- Injection site pain
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Kisspeptin-10 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 1 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: -20°C
- Reconstituted: Refrigerated 2-8°C (use promptly)
- Protect from direct light
- Limited stability after reconstitution
Scientific Studies
Published studies on Kisspeptin-10.
Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion
George JT, Millar RP, Anderson RA
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA
Related Peptides
Argipressin
5-20 IU or 1-4 mcg/kg · As clinically needed
Cetrorelix
0.25-3 mg per injection · Once daily (0.25 mg) or single dose (3 mg)
Gonadorelin
100-200 mcg per injection · 2-3 times per week
HCG
250-500 IU per injection · 2-3 times per week
α-MSH
0.5-2 mg per injection · Once daily or every other day
Oxytocin
10-40 IU intranasal or 50-200 mcg subcutaneous · 1-2 times daily